Skip to contentpdufa.bio

PROTECT registry (interim analysis)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

PROTECT registry (interim analysis) is a TriSalus Life Sciences, Inc. program in thyroid artery embolization. Its next catalyst is a Readout in Q1 2027.

TLSI catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Thyroid artery embolization. Sponsor: TriSalus Life Sciences, Inc. (TLSI). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q1 2027TLSI

Questions

When is PROTECT registry (interim analysis)'s next FDA decision or readout?

The next tracked catalyst for PROTECT registry (interim analysis) is a Readout in Q1 2027.

What happened at PROTECT registry (interim analysis)'s most recent FDA decision?

No FDA decision for PROTECT registry (interim analysis) is in our archive yet.

What is PROTECT registry (interim analysis) used for?

In our records PROTECT registry (interim analysis) is under review or in development for Thyroid artery embolization.

Who makes PROTECT registry (interim analysis)?

TriSalus Life Sciences, Inc. (TLSI).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.